ifenprodil has been researched along with Behavior Disorders in 1 studies
ifenprodil: NMDA receptor antagonist
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)[NCT05216614] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-14 | Withdrawn (stopped due to Unable to obtain investigational product) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifenprodil and Behavior Disorders
| Article | Year |
|---|---|
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication.
Topics: Animals; Donepezil; Humans; Indans; Mental Disorders; Models, Neurological; Neurotransmitter Agents; | 2015 |